Name : Human CD30/TNFRSF8 Protein
Product Source :
Recombinant Human CD30/TNFRSF8 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Phe19-Lys379.[Accession | P28908-1]
Molecular Weight :
The protein has a predicted MW of 41.3 kDa. Due to glycosylation, the protein migrates to 68-95 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human CD30 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Human CD30 is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized Human CD30, His Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Human CD30 Ligand, mFc (IgG2a) Tag with the EC50 of 10.5ng/ml determined by ELISA.
Background :
The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin’s disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin’s lymphomas (NHLs).
Synonyms :
CD30; CD30KI-1; CD30L receptor; TNFRSF8; D1S166EKi-1; CD30KI-1
References & Citations :
(1) Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol. 2009;647:174-85. doi: 10.1007/978-0-387-89520-8_12. PMID: 19760074.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
CG alpha Proteinweb
CD105/Endoglin Proteinsupplier
Popular categories:
Anti-Mullerian Hormone Receptor Type 2
E3 Ligases